Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.60 |
| ▸ | PREP | P48147 | 3/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5474103 | 0.96 | TMEM97 (0.65) | TMEM97SIGMAR1PREPKDM1ARCOR1 | |
| SCHEMBL18394326 | 0.91 | TMEM97 (0.61) | TMEM97SIGMAR1PREPKDM1ARCOR1 | |
| SCHEMBL4123903 | 0.91 | TMEM97 (0.58) | TMEM97SIGMAR1PREPKDM1ARCOR1 | |
| SCHEMBL2379314 | 0.88 | TMEM97 (0.60) | TMEM97SIGMAR1PREPKDM1ARCOR1 | |
| SCHEMBL4033512 | 0.87 | TMEM97 (0.68) | TMEM97SIGMAR1PREPNPC1RAB9A | |
| SCHEMBL27924857 | 0.87 | TMEM97 (0.63) | TMEM97SIGMAR1PREPKDM1ARCOR1 | |
| SCHEMBL5456476 | 0.87 | SIGMAR1 (0.63) | TMEM97SIGMAR1PREPKDM1ARCOR1 | |
| SCHEMBL27924834 | 0.86 | TMEM97 (0.62) | TMEM97SIGMAR1PREPKDM1ARCOR1 | |
| Water SCHEMBL27700641 | 0.86 | TMEM97 (0.67) | TMEM97SIGMAR1PREPNPC1RAB9A | |
| SCHEMBL2049032 | 0.86 | TMEM97 (0.58) | TMEM97SIGMAR1PREPKDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | TMEM97 1942/4885SIGMAR1 1778/4885PREP 890/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | TMEM97 1942/4885SIGMAR1 1778/4885PREP 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.